NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $9.16 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$9.19 +0.03 (+0.33%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vir Biotechnology Stock (NASDAQ:VIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$9.01▼$9.8150-Day Range$8.25▼$11.0952-Week Range$4.16▼$11.66Volume8.80 million shsAverage Volume1.90 million shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$20.88Consensus RatingModerate Buy Company Overview Vir Biotechnology, Inc. is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents. The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis. Vir entered into a notable collaboration with GlaxoSmithKline to develop monoclonal antibody therapies against SARS-CoV-2. Beyond its lead COVID-19 antibody program, Vir’s research focuses on next‐generation antiviral treatments and vaccines, employing deep sequencing and single-cell analysis to accelerate discovery. Preclinical and clinical trials are underway across multiple indications, reflecting the company’s commitment to addressing unmet medical needs in infectious diseases. Founded in 2017, Vir Biotechnology is headquartered in San Francisco, California, and operates research and development facilities in the United States and Europe. The company’s management team comprises experienced leaders in biotechnology and infectious disease research, driving strategic partnerships with academic institutions and global health organizations. Through its integrated platform and collaborative model, Vir aims to rapidly translate scientific insights into therapies that can improve outcomes for patients worldwide.AI Generated. May Contain Errors. Read More Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreVIR MarketRank™: Vir Biotechnology scored higher than 34% of companies evaluated by MarketBeat, and ranked 676th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialVir Biotechnology has a consensus price target of $20.88, representing about 127.9% upside from its current price of $9.16.Amount of Analyst CoverageVir Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($1.81) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Vir Biotechnology's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.19% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 10.81, which indicates bearish sentiment.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 8.81%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Vir Biotechnology this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,189,426.00 in company stock.Percentage Held by Insiders2.90% of the stock of Vir Biotechnology is held by insiders.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIR Stock News HeadlinesVir Biotechnology Adds Timothy Coughlin to Board, Audit ChairJune 10, 2026 | tipranks.comVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsJune 10, 2026 | businesswire.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 22 at 1:00 AM | Porter & Company (Ad)Barclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)June 8, 2026 | theglobeandmail.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | insidermonkey.comIs Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?June 7, 2026 | finance.yahoo.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 3,200 Shares of StockJune 3, 2026 | insidertrades.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $6.03 at the start of the year. Since then, VIR stock has increased by 51.9% and is now trading at $9.16. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.84. The firm earned ($0.03) million during the quarter, compared to analyst estimates of $55.49 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 53.31% and a negative net margin of 638.88%. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $150 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,142,858 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Top institutional shareholders of Vir Biotechnology include SB Investment Advisers UK Ltd. (6.49%), ADAR1 Capital Management LLC (1.63%), Dimensional Fund Advisors LP (1.60%) and Pictet Asset Management Holding SA (0.92%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Jason O'byrne, Mark Eisner, Ann M Hanly, Verneuil Vanina De, Brent Sabatini, Janet Napolitano and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Home Depot (HD), Moderna (MRNA) and Visa (V). Company Calendar Last Earnings5/06/2026Today6/22/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 VIR's financial health is in the Green zone, according to TradeSmith. VIR has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees580Year Founded2016Price Target and Rating Average Price Target for Vir Biotechnology$20.88 High Price Target$30.00 Low Price Target$14.00 Potential Upside/Downside+127.9%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$437.99 million Net Margins-638.88% Pretax Margin-675.39% Return on Equity-53.31% Return on Assets-41.76% Debt Debt-to-Equity RatioN/A Current Ratio7.11 Quick Ratio7.11 Sales & Book Value Annual Sales$68.56 million Price / Sales22.53 Cash FlowN/A Price / Cash FlowN/A Book Value$5.50 per share Price / Book1.67Miscellaneous Outstanding Shares168,650,000Free Float163,761,000Market Cap$1.54 billion OptionableOptionable Beta1.65 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VIR) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredA huge SpaceX error just led one stock to 3X move!SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....InvestPub | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts